105 related articles for article (PubMed ID: 19032230)
21. Cost effectiveness of asthma management strategies.
Thomas M; Haughney J; Price D
Pharmacoeconomics; 2002; 20(11):789. PubMed ID: 12201798
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness of asthma therapy: a comprehensive review.
Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
[TBL] [Abstract][Full Text] [Related]
23. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
24. Pharmacoeconomic review of medical management of persistent asthma.
Cheng JW; Arnold RJ
Allergy Asthma Proc; 2008; 29(2):109-22. PubMed ID: 18430307
[TBL] [Abstract][Full Text] [Related]
25. Leucotriene receptor antagonists for asthma can save millions, says NICE.
Wise J
BMJ; 2016 Dec; 355():i6835. PubMed ID: 28031161
[No Abstract] [Full Text] [Related]
26. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Markham A; Adkins JC
Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
[TBL] [Abstract][Full Text] [Related]
27. Revisiting the cost-effectiveness of omalizumab.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
[No Abstract] [Full Text] [Related]
28. Economic analysis of asthma practices.
Stempel DA
Am J Manag Care; 2000 Oct; 6(17 Suppl):S930-6; discussion S937-9. PubMed ID: 11184564
[TBL] [Abstract][Full Text] [Related]
29. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables.
Navarro RP; Parasuraman B
Manag Care Interface; 2005 Jun; 18(6):31-40. PubMed ID: 16018297
[TBL] [Abstract][Full Text] [Related]
31. [Medication adherence in asthma therapy--a structured review].
Fischer J; Wimmer A; Mahlich J
Pneumologie; 2013 Jul; 67(7):406-14. PubMed ID: 23797492
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
Brown R; Turk F; Dale P; Bousquet J
Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
[TBL] [Abstract][Full Text] [Related]
33. Bayesian cost-effectiveness analysis from clinical trial data.
O'Hagan A; Stevens JW; Montmartin J
Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
[TBL] [Abstract][Full Text] [Related]
34. Budget busters.
Cresswell J
Community Nurse; 1999 Oct; 5(9):10. PubMed ID: 10732567
[No Abstract] [Full Text] [Related]
35. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
[TBL] [Abstract][Full Text] [Related]
36. Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma.
Campbell JD; Blough DK; Sullivan SD
Ann Allergy Asthma Immunol; 2008 Nov; 101(5):474-81. PubMed ID: 19055200
[TBL] [Abstract][Full Text] [Related]
37. [Quality assurance of drug therapy for patients with asthma. Health economic analysis].
Søndergaard B; Thorleifsson S; Herborg H; Frøkjaer B; Hepler CD; Ersbøll BK
Ugeskr Laeger; 2000 Jan; 162(4):480-6. PubMed ID: 10697444
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed?
Haycox A; Featherstone R
J Med Econ; 2008; 11(3):525-39. PubMed ID: 19450102
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
40. [The pharmacoeconomics of asthma].
Plaza Moral V
Arch Bronconeumol; 1999 May; 35 Suppl 3():22-6. PubMed ID: 10410220
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
